Boston entrepreneur takes chair at F-star
F-star, the Cambridge biopharma company developing novel bispecific antibodies, has taken on Nessan Bermingham, Ph.D. as chairman of the board. He succeeds John Edwards who has been F-star’s chairman for seven years and will remain as a non-executive director.
Dr Bermingham is a highly qualified healthcare entrepreneur with an impressive track record of building, growing and consolidating both private and public biotech companies.
Based in Boston, USA, he has over a decade of experience in the life science industry, venture capital, secondary and public markets. Most recently, Nessan co-founded Intellia Therapeutics, a company developing potentially curative genome editing treatments for people living with severe and life-threatening diseases, and led it to a successful listing on NASDAQ.
John Haurum, CEO of Babraham Reseach Campus-based F-star said: “On behalf of the board, I would like to thank John Edwards for his remarkable seven-year tenure as our chairman and we look forward to his continuing contribution to F-star’s success.
“Nessan Bermingham brings a huge amount of experience, complementing the skills and expertise that we already have and I am confident he will play a vital role in supporting the next stage of our corporate development, helping us in achieving our ambition to become a key player in the immuno-oncology space.”
Dr Bermingham added: “It is an exciting time to be joining F-star’s board. The company is widely recognised as a leader in the bispecific antibody space and I am thrilled by the opportunities and prospects ahead of us.
“I am looking forward to supporting F-star in its mission to develop first-in-class therapies that have the potential to become life-changing treatments for cancer patients.”